Macrogen 100 SR Capsule
Rx75 mg • Capsule
ইঙ্গিত ও ব্যবহার
Nitrofurantoin (including the microcrystalline form) is used both to treat and to prevent acute or recurrent uncomplicated infections of the lower urinary tract, as well as pyelitis, whether these arise spontaneously or occur after a surgical procedure. It is particularly suited to treating infections caused by susceptible organisms such as *Escherichia coli*, enterococci, staphylococci, *Citrobacter*, *Klebsiella*, and *Enterobacter*.
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
Adults:
Adults and children over 12 years of age- Acute or recurrent uncomplicated urinary tract infections & pyelitis: Nitrofurantoin Modified Release 100 mg (one Umactin-BD 100 capsule) 2 times daily for 7 days. Surgical Prophylaxis: Nitrofurantoin Modified Release 100 mg (one Umactin-BD 100 capsule) 2 times daily on the day of the procedure and for 3 days thereafter. Children and Infants over 3 months of age- Acute urinary tract infections: Nitrofurantoin 3mg/kg day (Umactin Suspension 0.6ml/kg) in 4 divided doses for 7 days. Long term suppression of UTI: Nitrofurantoin 1mg/kg (Umactin Suspension 0.25ml/kg), once a day. Elderly: Provided there is no significant renal impairment, in which Nitrofurantoin is contra-indicated, the dosage should be that for any normal adult.
পার্শ্বপ্রতিক্রিয়া
Respiratory: If any of these reactions occur, the drug should be stopped. Acute pulmonary reactions can develop, and subacute reactions may take several months to settle once the drug has been withdrawn. Chronic pulmonary reactions are rare and are seen in patients who have been on continuous therapy for 6 months or longer; they are more common in elderly patients. ECG changes have been seen alongside these pulmonary reactions. Even minor symptoms such as fever, chills, cough and breathlessness may be meaningful and should not be ignored. Hepatic: Liver reactions, including cholestatic jaundice and chronic active hepatitis, occur rarely. Treatment should be stopped as soon as there is any sign of liver toxicity. Neurological: Peripheral neuropathy, including optic neuritis, with both sensory and motor symptoms, has been reported infrequently and may become severe or irreversible. Treatment should be stopped at the first sign of nerve involvement. Gastrointestinal: Nausea and loss of appetite have been reported.
সতর্কতা ও নিষেধাজ্ঞা
Warnings & Precautions
Nitrofurantoin does not effectively treat parenchymal infections of a unilaterally nonfunctioning kidney. In recurrent or severe cases, a surgical cause for the infection should be ruled out. Since underlying conditions may mask adverse reactions, Nitrofurantoin should be used cautiously in patients with pulmonary disease, hepatic dysfunction, neurological disorders, and allergic diathesis. Peripheral neuropathy, which may become severe or irreversible and can be life threatening, has occurred with this drug. Treatment should therefore be stopped at the very first signs of nerve involvement, such as tingling or numbness (paraesthesiae). Caution is also needed in patients with anaemia, diabetes mellitus, electrolyte imbalance, debilitating conditions, and vitamin B deficiency, particularly of folate. Chronic pulmonary reactions can develop gradually and without obvious warning, and they tend to occur more often in elderly patients, so close monitoring of pulmonary status is warranted during long-term therapy. In patients with suspected glucose-6-phosphate dehydrogenase deficiency, Nitrofurantoin should be discontinued at the first sign of haemolysis. Gastrointestinal reactions may be minimised by taking the drug with food or milk, or by adjusting the dosage.
নিষেধাজ্ঞা
Nitrofurantoin should not be used in patients with renal impairment (creatinine clearance under 60 ml/minute) or elevated serum creatinine, in infants under 3 months of age, or in pregnant women at term (during labour and delivery). This last precaution is because of a theoretical risk of haemolytic anaemia in the foetus or newborn, arising from the immaturity of their red blood cell enzyme systems. It is also contraindicated in anyone with known hypersensitivity to nitrofurantoin or other nitrofuran-class drugs.